Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.320
NA - Nord America 10.839
EU - Europa 7.389
SA - Sud America 2.651
AF - Africa 223
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 9
Totale 37.451
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.396
SG - Singapore 4.856
VN - Vietnam 3.946
HK - Hong Kong 3.776
CN - Cina 2.443
RU - Federazione Russa 2.283
BR - Brasile 2.144
IE - Irlanda 1.333
IT - Italia 1.220
DE - Germania 820
SE - Svezia 600
CA - Canada 249
AR - Argentina 242
GB - Regno Unito 229
KR - Corea 225
IN - India 215
ID - Indonesia 192
MX - Messico 143
AT - Austria 137
FI - Finlandia 130
UA - Ucraina 126
BD - Bangladesh 112
JP - Giappone 99
EC - Ecuador 89
NL - Olanda 89
FR - Francia 82
ZA - Sudafrica 72
TR - Turchia 63
IQ - Iraq 62
ES - Italia 60
PL - Polonia 54
BE - Belgio 44
CO - Colombia 39
PK - Pakistan 39
VE - Venezuela 39
MA - Marocco 33
PY - Paraguay 31
CL - Cile 29
SA - Arabia Saudita 28
AE - Emirati Arabi Uniti 27
MY - Malesia 26
IR - Iran 25
DK - Danimarca 24
UZ - Uzbekistan 24
TN - Tunisia 23
EG - Egitto 22
TH - Thailandia 22
UY - Uruguay 20
HU - Ungheria 19
RO - Romania 19
JO - Giordania 17
KZ - Kazakistan 16
LT - Lituania 14
AU - Australia 13
CZ - Repubblica Ceca 13
ET - Etiopia 13
DZ - Algeria 12
NO - Norvegia 12
PE - Perù 12
CH - Svizzera 11
KE - Kenya 11
LB - Libano 10
PT - Portogallo 10
RS - Serbia 10
AZ - Azerbaigian 9
PS - Palestinian Territory 9
SN - Senegal 9
CR - Costa Rica 8
IL - Israele 8
NP - Nepal 8
SK - Slovacchia (Repubblica Slovacca) 8
TT - Trinidad e Tobago 8
TW - Taiwan 8
DO - Repubblica Dominicana 7
LV - Lettonia 7
NG - Nigeria 7
NZ - Nuova Zelanda 7
OM - Oman 7
PH - Filippine 7
SY - Repubblica araba siriana 7
AL - Albania 6
GR - Grecia 6
HN - Honduras 6
CI - Costa d'Avorio 5
JM - Giamaica 5
KW - Kuwait 5
PA - Panama 5
AO - Angola 4
BH - Bahrain 4
BO - Bolivia 4
BW - Botswana 4
BY - Bielorussia 4
EE - Estonia 4
EU - Europa 4
GT - Guatemala 4
LK - Sri Lanka 4
MD - Moldavia 4
NI - Nicaragua 4
AM - Armenia 3
BG - Bulgaria 3
Totale 37.406
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.759
Singapore 2.775
Dublin 1.286
Ho Chi Minh City 1.273
Hanoi 968
Ashburn 876
Chandler 806
Princeton 744
Hefei 600
Ann Arbor 578
New York 541
Frankfurt am Main 494
Los Angeles 387
Santa Clara 360
Dallas 324
Lawrence 291
Fairfield 288
Beijing 287
Moscow 287
Altamura 268
Seoul 215
The Dalles 203
Chicago 194
São Paulo 189
Buffalo 184
Milan 184
Toronto 169
Jakarta 153
Andover 147
Wilmington 145
Nuremberg 135
Seattle 123
Cambridge 108
San Diego 105
Shanghai 105
Houston 103
Woodbridge 102
Da Nang 101
Haiphong 99
Ha Long 88
Quận Bình Thạnh 88
Rome 88
Ninh Bình 85
Biên Hòa 81
Rio de Janeiro 79
Vienna 66
Salt Lake City 65
Can Tho 64
Munich 64
Boardman 63
Thái Nguyên 62
Guangzhou 59
Tokyo 59
London 58
Hải Dương 57
Helsinki 56
Bắc Ninh 54
Pune 53
Washington 51
San Mateo 50
Lappeenranta 48
Mexico City 47
Vũng Tàu 47
Elk Grove Village 46
Bắc Giang 45
Brasília 44
Belo Horizonte 41
Brussels 40
Quận Một 40
Warsaw 37
Naples 36
Brooklyn 35
Kent 33
Guayaquil 32
Vinh 32
Curitiba 30
Atlanta 29
Buenos Aires 29
Dhaka 29
Phủ Lý 29
Dong Ket 28
Johannesburg 28
Porto Alegre 28
Quảng Ninh 28
Stockholm 28
Quận Tân Phú 27
Denver 26
Quận Phú Nhuận 26
Turku 26
Montreal 25
Phoenix 25
Quito 25
Quận Bảy 25
Zhengzhou 25
Chennai 23
Thu Dau Mot 23
Tianjin 23
Uyen Hung 23
Baghdad 22
Changsha 22
Totale 22.601
Salva come PNG Salva come JPEG
Nome #
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials 598
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 510
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 486
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes 457
Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction 432
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: Results from an Italian multicenter study 425
Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction between Supine Versus Upright Exercise Hemodynamic Testing 418
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 410
Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study 405
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 356
A matter of sex—persistent predictive value of MECKI score prognostic power in men and women with heart failure and reduced ejection fraction: a multicenter study 305
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 288
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 284
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials 250
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 241
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 239
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 235
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists 230
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 226
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 219
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 219
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 208
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure 206
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 198
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 196
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 190
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 184
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 183
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial 180
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 176
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 173
An uncommon and challenging finding regarding the tricuspid valve: Case report, clinical considerations, and practical management 168
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 166
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 164
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 163
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 160
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 158
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 157
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 156
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 156
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 151
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 142
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 142
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 141
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 141
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 141
Right ventricular reserve in cardiopulmonary disease: A simultaneous hemodynamic and three-dimensional echocardiographic study 132
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 129
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 127
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 127
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF 125
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease 120
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC 120
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 118
A 57-year-old man with rapidly progressive pulmonary hypertension 117
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 116
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 115
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 115
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 113
The chronic heart failure evolutions: Different fates and routes 112
Exercise Right Ventricular-Pulmonary Arterial Coupling and Functional Outcome in Patients Undergoing Surgery for Secondary Ischemic Mitral Regurgitation 111
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 109
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 108
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 107
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review 107
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 106
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 106
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF 104
An unusual case of cardiac aspergillosis 103
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities 102
Evolocumab and clinical outcomes in patients with cardiovascular disease 102
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 101
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 99
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation 98
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 97
Tailored approach to trans-catheter palliation of critically reduced pulmonary blood supply. Data on long term follow up 97
Trattamento conservativo della valvola mitrale in presenza di endocardite infettiva 96
Low dosage of cyclosporine and increased occurrence of chronic rejection in heart-transplanted patients 96
Cardiac contractility modulation in heart failure with reduced ejection fraction: critical review of evidence and application perspectives [Modulazione della contrattilità cardiaca nello scompenso cardiaco a frazione di eiezione ridotta: revisione critica delle evidenze ed aspetti decisionali pratici] 96
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 96
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study 95
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial 95
Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy 95
Incidental cardiac aspergillomas in an immunocompromised woman 94
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 93
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels 92
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 92
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction 91
Aspirin Desensitization in Patients with Coronary Artery Disease 90
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 89
Trapianto cardiaco in età pediatrica: esperienza in 34 casi 89
Sex-related differences in patients with coronavirus disease 2019: Results of the Cardio-COVID-Italy multicentre study 89
Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF Registry) 88
Surgical ventricular reverse remodeling in severe ischemic dilated cardiomyopathy: The relevance of the left ventricular equator as a prognostic factor 88
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol 88
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 87
Ejection fraction of 20% or less is not a contraindication to cardiac surgery 87
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs 87
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial 86
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis 85
Totale 16.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021494 0 0 0 0 0 49 73 54 66 68 81 103
2021/20222.953 79 76 77 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/202512.162 466 1.221 441 471 1.283 473 1.104 347 1.518 1.639 946 2.253
2025/202615.315 4.379 3.430 1.888 2.627 2.724 267 0 0 0 0 0 0
Totale 39.164